Impress employers and recruiters.
Choose from hundreds of resume examples.

Target Resume Now

About the Role

The Director of SEC Reporting and Technical Accounting will build and run SEC reporting processes for a newly public, fast-moving clinical-stage biotechnology company. This individual will own SEC reporting operations, internal controls, financial statement preparation, and filings (10-Qs/10-Ks, annual proxy). Responsibilities also include technical accounting, contract review, and analysis of accounting memos. This is a hands-on role requiring collaboration with internal and external partners.

Responsibilities

Own the preparation and drafting of 10-Qs/10-Ks and annual proxy in accordance with US GAAP and SEC requirements, meeting reporting deadlines.
Develop and maintain SEC reporting policies, procedures, and internal controls for a high-growth environment.
Manage external audit relationships and lead audit readiness processes.
Own the accounting for equity compensation (ASC 718) and income tax (ASC 740).
Review new contracts for proper accounting treatment and coordinate with FP&A on budget and forecast treatment.
Prepare or supervise the preparation of technical accounting memos in accordance with US GAAP.
Administer the Company’s equity plan(s), coordinating with legal and HR.
Manage the Company’s annual income tax requirements, coordinating with external tax providers.
Assist in the preparation of quarterly Disclosure Committee and Audit Committee communications.
Implement and optimize an equity administration system.
Assist in hiring and developing a high-performing accounting and finance team.

Requirements

10+ years of progressive finance and accounting experience.
CPA required.
Public accounting background preferred.
Strong knowledge of public company requirements, including SEC reporting, internal controls (SOX), financial planning, and cross-functional alignment.
Deep technical accounting knowledge (US GAAP), including equity compensation (ASC 718), income tax (ASC 740), R&D accruals, clinical trial accounting, and pre-clinical/clinical stage company financials.
Experience managing Big 4 or national firm audits.
Prior experience supporting or executing a public offering (IPO, follow-on, crossover) preferred.
Demonstrated experience building finance and accounting infrastructure from the ground up in preparation for and through a biotechnology IPO preferred.
Excellent judgment and high integrity.
Ability to operate with minimal overhead in a fast-moving environment.
Ability to thrive in a nimble environment, bringing public company rigor to a private-stage company, and building scalable systems without unnecessary overhead.
Strong written and verbal communication skills.
Collaborative, team-oriented approach.
Ability to thrive in a fast-paced, dynamic environment and remain comfortable with change and ambiguity.
Flexible, proactive, and hands-on mindset with a roll-up-your-sleeves, can-do attitude.

Skills

SEC reporting
Internal controls (SOX)
Financial planning
US GAAP
Equity compensation (ASC 718)
Income tax (ASC 740)
R&D accruals
Clinical trial accounting
Pre-clinical/clinical stage company financials
Audit management
Public offering support
Finance and accounting infrastructure development
Written communication
Verbal communication
Collaboration
Teamwork
Adaptability
Proactiveness
Hands-on approach

Location

Remote

Work Type

Full-time

Experience Level

10+ years

Education Level

CPA required

Salary/Compensations

$200,000 - $240,000

Benefits

Competitive total rewards package
Annual bonus
Equity
Comprehensive benefits offering

About the Company

Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases.
Our lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM).
Braveheart’s goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, reversibility and reducing prescribing complexity.
With a proven leadership team, a strong financial foundation, and a high-value late-stage asset, Braveheart Bio represents an outstanding opportunity for ambitious, mission-driven professionals to make a tangible impact in a high-profile and rapidly evolving therapeutic area.

Equal Opportunity

We are an equal opportunity employer.
We are committed to inclusion and diversity, and we do not discriminate on the basis of race, gender, religion, gender, sexual orientation, age, color, marital status, veteran status, disability status, national origin, or any characteristic protected under applicable law.
Braveheart participates in the federal E‑Verify program to confirm employment authorization for all new hires.